Queensland and the Northern Territory have banned puberty blockers and gender-affirming hormones for trans and gender diverse young people in their public health systems, despite an independent evaluation finding that Queensland's gender service provided safe, evidence-based care. The bans were issued without consultation, survived a Supreme Court challenge via ministerial direction, and are now tied to an NHS England trial that has been paused. The human cost lands on teenagers who were already waiting.

What the Queensland Government's own review actually found

This is the detail that stops me in my tracks every time I read it. Between December 2023 and June 2024, an external clinical service evaluation of Queensland Children's Gender Services found that the service was providing safe care, consistent with evidence-based national guidelines. There was no evidence of patients or their families being hurried into decisions. The service was stretched, yes, under-resourced for the demand it was facing, and a networked approach was recommended to extend its reach. But the care itself? Safe. Evidence-based. Doing what it was supposed to do.

Then in January 2025, the Queensland Government banned it anyway.

The Health Service Directive, QH-HSD-058, declared that Queensland public health services could not initiate puberty blockers or gender-affirming hormonal treatment for anyone under 18. It was issued without the legally required consultation with Queensland Health. The Vine Review it cited as justification had not yet reported. The national guidelines being developed by the NHMRC did not yet exist. The ban came first. The reasons came later.

A court said no. The government found another way

When the directive was challenged in the Supreme Court of Queensland, Justice Callaghan ordered it be set aside. That was in October 2025. A significant moment, and I imagine it felt like one for the families who had been fighting.

On the same day the court ruling landed, the Queensland Government issued a Ministerial Direction to maintain the ban regardless. QH-MD-002, this time framed as a direction rather than a directive, keeping the prohibition in place until January 2032. When the Supreme Court says the mechanism is unlawful and the government's immediate response is to reach for a different mechanism to achieve the same outcome, that is not a government engaged in a good-faith review of the evidence. That is a government that had already decided.

The justification offered when the ban was extended was particularly striking. The Queensland Minister for Health stated the ban would remain until the NHS England Pathways trial is complete in 2031. Except the Pathways trial has not started. It was paused in February 2026 after safety concerns were raised by the Medicines and Healthcare Products Regulatory Agency. The goalposts are not just moving; they are being attached to something that does not yet exist.

The Northern Territory followed within days

Two days after Queensland extended its ban, the Northern Territory Minister for Health announced that adolescents in the Territory would also lose access to puberty blockers and gender-affirming hormones through public health services. There was no separate review, no independent evidence base, no clinical evaluation of their own services. Queensland moved, and the Territory followed.

What this tells you is that these bans are not primarily clinical decisions. They are political ones, moving in formation, borrowing the language of caution and evidence while acting in the absence of both.

Who actually carries the cost

The article in the Australian Nursing and Midwifery Journal cites the Trans Pathways study, and I think the number deserves to sit without decoration: 48.1% of trans and gender diverse young people aged between 14 and 25 in Australia reported attempting suicide. Nearly half. And that was before the bans, when the barriers were already cost, long waiting lists, and limited access. The bans have made those barriers absolute for families relying on the public system.

What I hear, over and over, from people in situations like this is not abstract distress about policy. It is the specific, grinding weight of a teenager who knows what they need, whose family knows what they need, whose clinicians know what they need, and who cannot access it because a politician decided the evidence was not yet settled. Delay is not neutral. Unwanted puberty changes do not wait for a ministerial review cycle. The harm that accumulates in the gap between need and access is real, measurable, and preventable.

The autonomy point made in Pheona van Huizen's piece matters here too. In Australia, there is no fixed age at which a person under 18 is considered automatically incapable of consenting to medical treatment. Gillick competence, the principle that capacity is determined by a young person's ability to understand the nature of the treatment, is well established in common law. These bans override that framework entirely, removing the clinical and legal judgment that was already in place and replacing it with a blanket political prohibition.

What good care actually looks like

AusPATH's Project 491 is attempting to help affected young people access care through alternative routes, and that matters as an immediate response. But it should not have to exist. What should exist is a well-resourced, networked public gender service doing what the Queensland evaluation said the existing service was already doing: providing safe, evidence-based care, without rushing people, without gatekeeping beyond what clinical good practice requires, and without politicians making the final call on who gets treatment.

The NHMRC is developing new national clinical practice guidelines, with interim advice expected in the middle of 2026. The working title of those guidelines uses the term "gender dysphoria", which the ANMJ piece notes with concern, and rightly so. A de-pathologising, informed consent model of care is what the evidence and the ethics point toward. Guidelines built around a diagnostic label risk reintroducing the very gatekeeping that causes so much of the harm in the first place.

Nurses, midwives, and frontline clinicians across Queensland and the Northern Territory are still in contact with these young people and their families. They cannot prescribe what has been banned, but they can refuse to pretend the bans are clinically justified. They can document the harm. They can advocate within their institutions. They can make sure young people and families know that the care they are being denied is not experimental, not unsafe, and not withheld on clinical grounds. That knowledge matters. It is the difference between a teenager who believes the system has decided they are not worth treating and one who knows the system has been captured by politics, and that the clinicians around them know it too.